-
公开(公告)号：US06306830B1
公开(公告)日：2001-10-23
申请号：US09008097
申请日：1998-01-16
申请人： H. Kirk Hammond , Paul A. Insel , Peipei Ping , Steven R. Post , Meihua Gao
发明人： H. Kirk Hammond , Paul A. Insel , Peipei Ping , Steven R. Post , Meihua Gao
IPC分类号： A61K4800
CPC分类号： C12N9/88 , A61K48/00 , C12N2799/022
摘要： The present invention relates to methods and compositions for enhancing cardiac function in mammalian hearts by inserting transgenes that increase &bgr;-adrenergic responsiveness within the myocardium. The present invention can thus be used in the treatment of heart disease, especially congestive heart failure.
摘要翻译： 本发明涉及通过插入增加心肌内β-肾上腺素能反应性的转基因来增强哺乳动物心脏功能的方法和组合物。 因此，本发明可用于治疗心脏病，特别是充血性心力衰竭。
-
公开(公告)号：US07846664B2
公开(公告)日：2010-12-07
申请号：US12096628
申请日：2006-12-07
申请人： Paul A. Insel , Lingzhi Zhang , Fiona Murray , Joan R. Kanter , Thomas Kipps , Laura Rassenti
发明人： Paul A. Insel , Lingzhi Zhang , Fiona Murray , Joan R. Kanter , Thomas Kipps , Laura Rassenti
CPC分类号： C12Q1/6886 , C12Q2600/158
摘要： The present invention provides diagnostic methods and kits for diagnosis of chronic lymphocytic leukemia (CLL) by determining expression levels of isoforms of cyclic nucleotide phosphodiesterases (PDEs) associated with CLL particularly, PDE7B and/or PDE3B, and a ratio of mRNA expression of PDE7B to PDE3B. The present invention provides that CLL lymphocytes uniformly expressed high levels of PDE7B and low levels of PDE3B relative to those of normal lymphocytes. A method of treatment and a pharmaceutical composition for CLL comprising one or more therapeutic agents capable of modulating expression or activity levels of isoforms of PDEs associated with CLL, and/or reversing the ratio of PDE7B/PDE3B mRNA expression levels are also provided.
摘要翻译： 本发明通过确定与CLL特别是PDE7B和/或PDE3B相关的环核苷酸磷酸二酯酶（PDE）的同种型的表达水平，以及PDE7B的mRNA表达比例与PDE7B的mRNA表达的比例，提供了用于诊断慢性淋巴细胞性白血病（CLL）的诊断方法和试剂盒 PDE3B。 本发明提供了CLL淋巴细胞相对于正常淋巴细胞均匀表达高水平的PDE7B和低水平的PDE3B。 还提供了一种治疗方法和用于CLL的药物组合物，其包含一种或多种能够调节与CLL相关的PDE的同种型的表达或活性水平和/或逆转PDE7B / PDE3B mRNA表达水平的比例的治疗剂。
-
3.发明授权Polynucleotide encoding human adenylylcyclase VI and uses thereof for enhancing cardiac function 有权编码人腺苷酸环化酶VI的多核苷酸及其用于增强心脏功能的用途公开(公告)号：US07235236B2
公开(公告)日：2007-06-26
申请号：US10942072
申请日：2004-09-14
申请人： H. Kirk Hammond , Paul A. Insel , Peipei Ping , Steven R. Post , Meihua Gao
发明人： H. Kirk Hammond , Paul A. Insel , Peipei Ping , Steven R. Post , Meihua Gao
CPC分类号： C12N9/1205 , A01K2217/05 , A61K38/00 , A61K38/1787 , A61K48/00 , A61K48/0058 , A61K48/0075 , C12N9/88 , C12N15/86 , C12N2710/10343 , C12N2750/14143 , C12N2799/025 , C12N2830/42
摘要： The present invention relates to polynucleotides encoding human adenylylcyclase VI and uses thereof for enhancing cardiac function. The present invention can thus be used in the treatment of heart disease, especially congestive heart failure.
摘要翻译： 本发明涉及编码人腺苷酸环化酶VI的多核苷酸及其用于增强心脏功能的用途。 因此，本发明可用于治疗心脏病，特别是充血性心力衰竭。
-
公开(公告)号：US20090131353A1
公开(公告)日：2009-05-21
申请号：US12096628
申请日：2006-12-07
申请人： Paul A. Insel , Lingzhi Zhang , Fiona Murray , Joan R. Kanter , Thomas Kipps , Laura Rassenti
发明人： Paul A. Insel , Lingzhi Zhang , Fiona Murray , Joan R. Kanter , Thomas Kipps , Laura Rassenti
IPC分类号： A61K48/00 , C12Q1/68 , A61K31/7105 , A61P35/02 , A61K31/711
CPC分类号： C12Q1/6886 , C12Q2600/158
摘要： The present invention provides diagnostic methods and kits for diagnosis of chronic lymphocytic leukemia (CLL) by determining expression levels of isoforms of cyclic nucleotide phosphodiesterases (PDEs) associated with CLL particularly, PDE7B and/or PDE3B, and a ratio of mRNA expression of PDE7B to PDE3B. The present invention provides that CLL lymphocytes uniformly expressed high levels of PDE7B and low levels of PDE3B relative to those of normal lymphocytes. A method of treatment and a pharmaceutical composition for CLL comprising one or more therapeutic agents capable of modulating expression or activity levels of isoforms of PDEs associated with CLL, and/or reversing the ratio of PDE7B/PDE3B mRNA expression levels are also provided.
摘要翻译： 本发明通过确定与CLL特别是PDE7B和/或PDE3B相关的环核苷酸磷酸二酯酶（PDE）的同种型的表达水平，以及PDE7B的mRNA表达比例与PDE7B的mRNA表达的比例，提供了用于诊断慢性淋巴细胞性白血病（CLL）的诊断方法和试剂盒 PDE3B。 本发明提供了CLL淋巴细胞相对于正常淋巴细胞均匀表达高水平的PDE7B和低水平的PDE3B。 还提供了一种治疗方法和用于CLL的药物组合物，其包含一种或多种能够调节与CLL相关的PDE的同种型的表达或活性水平和/或逆转PDE7B / PDE3B mRNA表达水平的比例的治疗剂。
-
公开(公告)号：US08114590B2
公开(公告)日：2012-02-14
申请号：US12960955
申请日：2010-12-06
申请人： Paul A. Insel , Lingzhi Zhang , Fionna Murray , Joan R. Kanter , Thomas Kipps , Laura Rassenti
发明人： Paul A. Insel , Lingzhi Zhang , Fionna Murray , Joan R. Kanter , Thomas Kipps , Laura Rassenti
CPC分类号： C12Q1/6886 , C12Q2600/158
摘要： The present invention provides diagnostic methods and kits for diagnosis of chronic lymphocytic leukemia (CLL) by determining expression levels of isoforms of cyclic nucleotide phosphodiesterases (PDEs) associated with CLL, particularly, PDE7B and/or PDE3B, and a ratio of mRNA expression of PDE7B to PDE3B. The present invention provides that CLL lymphocytes uniformly expressed high levels of PDE7B and low levels of PDE3B relative to those of normal lymphocytes. A method of treatment and a pharmaceutical composition for CLL comprising one or more therapeutic agents capable of modulating expression or activity levels of isoforms of PDEs associated with CLL, and/or reversing the ratio of PDE7B/PDE3B mRNA expression levels are also provided.
摘要翻译： 本发明通过测定与CLL，特别是PDE7B和/或PDE3B相关的环状核苷酸磷酸二酯酶（PDEs）的同种型的表达水平以及PDE7B的mRNA表达的比例来提供用于诊断慢性淋巴细胞性白血病（CLL）的诊断方法和试剂盒 到PDE3B。 本发明提供了CLL淋巴细胞相对于正常淋巴细胞均匀表达高水平的PDE7B和低水平的PDE3B。 还提供了一种治疗方法和用于CLL的药物组合物，其包含一种或多种能够调节与CLL相关的PDE的同种型的表达或活性水平和/或逆转PDE7B / PDE3B mRNA表达水平的比例的治疗剂。
-
公开(公告)号：US06752987B1
公开(公告)日：2004-06-22
申请号：US09472667
申请日：1999-12-27
申请人： H. Kirk Hammond , Paul A. Insel , Peipei Ping , Steven R. Post , Meihua Gao
发明人： H. Kirk Hammond , Paul A. Insel , Peipei Ping , Steven R. Post , Meihua Gao
IPC分类号： A61K3500
CPC分类号： C12N15/86 , A01K2217/05 , A61K38/00 , A61K48/00 , C07K14/50 , C12N9/88 , C12N2710/10343 , C12N2830/008 , C12N2830/42
摘要： The present invention relates to methods and compositions for enhancing cardiac function in mammalian hearts by inserting transgenes that increase beta-adrenergic responsiveness within the myocardium. The present invention can thus be used in the treatment of heart disease, especially congestive heart failure.
摘要翻译： 本发明涉及通过插入增加心肌内β-肾上腺素能反应性的转基因来增强哺乳动物心脏功能的方法和组合物。 因此，本发明可用于治疗心脏病，特别是充血性心力衰竭。
-
公开(公告)号：US20110117562A1
公开(公告)日：2011-05-19
申请号：US12960955
申请日：2010-12-06
申请人： Paul A. Insel , Lingzhi Zhang , Fionna Murray , Joan R. Kanter , Thomas Kipps , Laura Rassenti
发明人： Paul A. Insel , Lingzhi Zhang , Fionna Murray , Joan R. Kanter , Thomas Kipps , Laura Rassenti
CPC分类号： C12Q1/6886 , C12Q2600/158
摘要： The present invention provides diagnostic methods and kits for diagnosis of chronic lymphocytic leukemia (CLL) by determining expression levels of isoforms of cyclic nucleotide phosphodiesterases (PDEs) associated with CLL, particularly, PDE7B and/or PDE3B, and a ratio of mRNA expression of PDE7B to PDE3B. The present invention provides that CLL lymphocytes uniformly expressed high levels of PDE7B and low levels of PDE3B relative to those of normal lymphocytes. A method of treatment and a pharmaceutical composition for CLL comprising one or more therapeutic agents capable of modulating expression or activity levels of isoforms of PDEs associated with CLL, and/or reversing the ratio of PDE7B/PDE3B mRNA expression levels are also provided.
摘要翻译： 本发明通过测定与CLL，特别是PDE7B和/或PDE3B相关的环状核苷酸磷酸二酯酶（PDEs）的同种型的表达水平以及PDE7B的mRNA表达的比例来提供用于诊断慢性淋巴细胞性白血病（CLL）的诊断方法和试剂盒 到PDE3B。 本发明提供了CLL淋巴细胞相对于正常淋巴细胞均匀表达高水平的PDE7B和低水平的PDE3B。 还提供了一种治疗方法和用于CLL的药物组合物，其包含一种或多种能够调节与CLL相关的PDE的同种型的表达或活性水平和/或逆转PDE7B / PDE3B mRNA表达水平的比例的治疗剂。
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.016 秒)
